Abstract Evidence suggests that activation of the tryptophan catabolite (TRYCAT) pathway is involved in the pathophysiology of schizophrenia.
kynurenine, in 40 healthy controls and in schizophrenic patients with (n = 40) and without (n = 40) deficit, defined according to the Schedule for the Deficit Syndrome (SDS). Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia. Participants with deficit schizophrenia show increased IgA responses to xanthurenic acid, picolinic acid, and quinolinic acid and relatively lowered IgA responses to kynurenic and anthranilic acids, as compared to patients with nondeficit schizophrenia. Both schizophrenia subgroups show increased IgA responses to 3-OH-kynurenine as compared to controls. The IgA responses to noxious TRYCATs, namely xanthurenic acid, picolinic acid, quinolinic acid, and 3-OHkynurenine, but not protective TRYCATS, namely anthranilic acid and kunyrenic acid, are significantly higher in deficit schizophrenia than in controls. The negative symptoms of schizophrenia are significantly and positively associated with increased IgA responses directed against picolinic acid and inversely with anthranilic acid, whereas no significant associations between positive symptoms and IgA responses to TRYCATs were found. In conclusion, primary deficit schizophrenia is characterized by TRYCAT pathway activation and differs from nondeficit schizophrenia by a highly specific TRYCAT pattern suggesting increased excitotoxicity, cytotoxicity, and neurotoxicity, as well as inflammation and oxidative stress. The specific alterations in IgA responses to TRYCATs provide further insight for the biological delineation of deficit versus nondeficit schizophrenia.
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Introduction
In 1995, it was hypothesized that activated immuneinflammatory pathways could contribute to aberrant neurodevelopmental trajectories after infections in utero through different mechanisms, including but not limited to neuroinflammation, activation of oxidative and nitrosative (O&NS) pathways, and stimulation of the tryptophan catabolite (TRYCAT) pathway, leading to changes in glutamate production and Nmethyl-D-aspartate receptor (NMDAr) function [1] . Since then, accumulating evidence indicates that immune activation, TRYCAT pathway activation, and NMDAr dysfunctions may play a significant role in the neuroprogressive processes in schizophrenia, part via impacts on neuronal circuitry and brain functions [2] [3] [4] .
There is now evidence that the acute and chronic phases of schizophrenia as well as drug-naive first episode psychosis are accompanied by immune activation and a low-grade inflammatory response as indicated by increased peripheral levels of acute phase reactants, complement factors, and cytokine levels, thereby indicating an immune activation signature with involvement of M1 macrophages, as well as T helper (Th) 1, Th2, and regulatory T (Treg) cells [5] [6] [7] [8] [9] . For example, schizophrenia is accompanied by increased levels on interleukin-6 (IL-6), IL-1β, and soluble IL-2 receptor levels, indicating T cell activation [9] [10] [11] . In addition, schizophrenia is associated with increased nitric oxide (NO) and nitro-tyrosine levels and multiple signs of lipid peroxidation [12] . Increased peripheral levels of some of those M1 and Th1 cytokines together with increased O&NS may drive neurotoxic effects, apoptotic processes and lowered neurogenesis, and a dysregulation of genes involved in microRNA (miRNA) machinery and neuroplasticity, contributing to neuroprogression [7] . There is also some evidence that increased gut permeability and changes in the microbiome may play a role in the immune pathophysiology of schizophrenia [13] .
Th1-and M1-associated pro-inflammatory immune activation, as well as oxidative stress, stimulate the TRYCAT pathway, via the induction of indoleamine-2,3-dioxygenase (IDO), which takes away tryptophan from 5-HT production and drives it down the TRYCAT pathway leading to increased TRYCAT production [2] . Some TRYCATs are neurotoxic, including 3-hydroxykynurenine (3-OH-kynurenine) and quinolinic acid, whereas other TRYCATs, such as kynurenic acid, may have neuroprotective effects [2] . The latter TRYCAT also inhibits the alpha 7 nicotinic acetylcholine receptor (α7nAChr), resulting in lowered glutamate release [14] . Quinolinic acid also activates the NMDAr, which cont r i b u t e s t o e x c i t o t o x i c i t y [ 1 5 ] c o n t r i b u t i n g t o neuroprogression [3] . Picolinic acid may antagonize the neurotoxic activities of quinolinic acid but may also contribute to macrophage-modulated inflammation [16] . Anthranilic acid in turn inhibits the conversion of 3-hydroxyanthranilic acid into quinolinic acid and picolinic acid and therefore may have protective functions [17, 18] . Xanthurenic acid may be neuroprotective by lowering the levels of 3-OH-kynurenine [19] , but this TRYCAT also induces apoptosis and impairs mitochondrial function, as well as increasing intracellular calcium concentration, thereby exerting excitatory functions in the brain [20] .
Clinical studies show that the TRYCAT pathway may be activated in schizophrenia with resultant lowering of tryptophan levels [21] [22] [23] . Furthermore, increased kynurenate levels (namely kynurenine and kynurenic acid) have been reported in the postmortem brain tissue and cerebral spinal fluid (CSF) of schizophrenic patients [24] [25] [26] . Other authors found increased levels of anthranilic acid in schizophrenia which could explain lowered 3-OH-kynurenine [27] . Fazio et al. [28] proposed that lowered xanthurenic acid could be a trait marker of schizophrenia and first-episode schizophrenia. Recent reviews underscore the role of increased kynurenic acid in the pathophysiology of schizophrenia, including NMDAr and glutamate dysfunction, as well as neurocognitive deficits, at least in part via α7nAChr inhibition [29, 30] . Interestingly, schizophrenic patients with increased anti-gliadin IgG autoantibodies have elevated kynurenine levels and a higher kynurenine/tryptophan ratio, suggesting that gluten sensitivity and thus gut-derived inflammation could contribute to TRYCAT pathway activation in schizophrenia [31] .
Schizophrenia is a heterogeneous phenotype, with a subset of patients presenting negative symptoms and cognitive dysfunction over the course of their illness, whereas others experience mild or even a relative absence of these symptoms [32, 33] . A classical way to parse the phenotypic heterogeneity of schizophrenia has been to group patients with chronic, enduring, and primary negative symptoms (i.e., apathy, social inhibition/withdrawal, flat affect, monotonous speech, lack of interest, anhedonia, and not being able to maintain planned activities) and to label these correlated symptoms as deficit schizophrenia [34] [35] [36] . Deficit schizophrenia differs from nondeficit forms of the condition, with worse long-term prognosis, poorer social functioning, and specific psychopathological and neurocognitive correlates [35, 37] . This suggests that deficit schizophrenia may have different pathophysiological underpinnings that contribute to its more pernicious course. No study to date has investigated whether deficit schizophrenia is associated with different patterns or magnitude of TRYCAT pathway activation, as compared to nondeficit presentations.
This study was performed to delineate the TRYCAT profile in patients with and without deficit schizophrenia. IgAmediated immune responses directed to xanthurenic, picolinic, quinolinic, kynurenic, and anthranilic acid, as well as 3-OH-kynurenine, were measured in both deficit and nondeficit schizophrenia [38, 39] . As well as other cell types, intestinal cells and dendritic cells of the mesenteric lymph nodes express IDO [40, 41] . Thus, following mucosaassociated inflammation, the induction of IDO leads to elevated levels of TRYCATs and consequently IgA-mediated responses directed against TRYCATs [38, 39] . The a priori hypothesis are that (a) the TRYCAT pathway is activated in schizophrenia, (b) schizophrenia is accompanied by increased kynurenic acid, (c) deficit schizophrenia shows a TRYCAT profile characteristic of an increased neurotoxic potential including increased quinolinic acid and 3-OH-kynurenine levels, and (d) the negative symptoms of schizophrenia are associated with the same neurotoxic TRYCATs.
Subjects and Methods

Subjects
This is a cross-sectional study that enrolled Thai adults (aged 18-65 years old) of both sexes. Consecutive schizophrenic outpatients in a stabilized or compensated state of illness were recruited at the Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. The diagnosis of schizophrenia was made using the diagnostic criteria for schizophrenia of the DSM-IV-TR using the validated Thai version of the Mini-International Neuropsychiatric Interview (M.I.N.I.) [42] . Both patients and controls were interviewed with the M.I.N.I. The controls are apparently healthy normal individuals recruited from the same catchment population. Exclusion criteria for patients were as follows: a current and life-time diagnosis of axis-I DSM IV/DSM V mental disorder other than schizophrenia, such as depression, bipolar disorder, substance use disorders, and psycho-organic disorders. Exclusion criteria for both schizophrenic patients and healthy volunteers were (a) medical illnesses, such as inflammatory bowel disease, rheumatoid arthritis, chronic obstructive pulmonary disease, multiple sclerosis, neurodegenerative disorders, diabetes type 1 and 2, dementia, Parkinson's and Huntington's disease, and stroke; (b) treatments with immunomodulatory drugs, including glucocorticoids and antioxidant supplements (n3 poly-unsaturated fatty acids, N-acetyl cysteine); (c) alcohol abuse; and (d) immune-inflammatory responses in the month prior to the acquisition of blood samplings. In addition, healthy controls were excluded if they had a positive familial history of schizophrenia.
Deficit schizophrenia was defined according to the Schedule for the Deficit Syndrome (SDS) [43] , comprising at least two of the following six features with a clinically relevant severity: restricted affect, diminished emotional range, poverty of speech, curbing of interest, diminished sense of purpose, and diminished social drive, for the preceding 12 months. Inclusion in the subtype of primary deficit schizophrenia also required that the symptoms are not secondary to extrapyramidal side effects induced by antipsychotic medication. All participants, controls, and patients provided written informed consent prior to participation in this study. The study was conducted according to Thai and international ethics and privacy laws. Approval for the study was obtained from the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, which is in compliance with the International Guideline for Human Research protection as required by the Declaration of Helsinki, The Belmont Report, CIOMS Guideline, and International Conference on Harmonization in Good Clinical Practice (ICH-GCP).
Methods
Both patients and healthy controls underwent a comprehensive evaluation by senior research psychiatrists and trained clinical assistants (master degree in mental health) using a semi-structured interview (including the M.I.N.I.), which comprised a clinical assessment (made by the senior psychiatrist), coupled with measurements of the Schedule for Deficit Syndrome (SDS) [43] , the Scale for the Assessment of Negative Symptoms (SANS) [44] , the Positive and Negative Syndrome Scale (PANSS) [45] , and the Brief Psychiatric Rating Scale (BPRS) [46] . We registered smoking behavior and measured severity of nicotine dependence using the Fagerstrom Nicotine Dependence Scale [47] . Blood samples were taken at 8.00 a.m. on the same day as the clinical interviews. [38, 39, 48] The six TRYCATs were dissolved in 200 μL dimethylsulfoxide (DMSO) (Acros). Bovine serum albumin (BSA) (ID Bio) was dissolved in 3 mL 2-morpholino-ethanesulfonic acid monohydrate (MES) buffer 10 −1 M at pH = 6.3 (Acros). F i f t y m i c r o l i t e r s o f T M B s u b s t r a t e ( 3 , 3 ′ , 5 , 5 ′ -tetramethylbenzidine, SouthernBiotech) was added and incubated for 10 min in the dark. The reaction was stopped using 50 μL of TMB stop solution (SouthernBiotech). Optical densities (ODs) were measured at 450 nm using Varioskan Flash (Thermo Scientific). All assays were carried out in one and the same run by the same operator (SS) who was blind to all clinical results. All assays were carried out in duplicate. The analytical intra-assays CV values were <7%.
Synthesis of TRYCATs Conjugates
Statistics
We used analyses of contingency tables (χ 2 test) to check the associations between two sets of categorical variables and analyses of variance (ANOVA) to assess between-group differences in continuous variables. We employed multivariate general linear model (GLM) analyses to check the multivariate effects of explanatory variables (e.g., diagnosis, BMI, age, sex, education, and work status) on TRYCAT levels as dependent variables. Tests for between-subject effects were subsequently used to delineate the univariate effects of the statistically significant explanatory variables. Automatic stepwise binary logistic regression analysis was employed to delineate the significant TRYCATs that predict schizophrenia versus controls. Automatic stepwise multinomial logistic regression analysis was employed to delineate the TRYCATs that best separate deficit from nondeficit schizophrenia and both groups from controls, while adjusting for sociodemographic data. Automatic stepwise regression analyses was used to determine the significant TRYCATs that predict the total BPRS score and the SANS and PANSS (sub)scale scores. We used z transformations of the OD values of the IgA responses directed to TRYCATs [48] . As an index of TRYCAT pathway activation (TOTAL-TP), we used the total sum of all z scores of the six TRYCATs. Given that the QA/KA ratio is commonly used as a neurotoxic/neuroprotective index, z scores of the IgA responses were used to give the QA/KA ratio (zQA-KA). Analyses were checked for (multi)collinearity using the SPSS linear regression subprogram. Collinearity was considered to be present when tolerance <2 and VIF >5. In case two or more variables caused (multi)collinearity, we combined the z scores of these variables into one index. Power analysis showed that for an effect size f = 0.30, alpha = 0.05, power = 0.8, the required sample size for an ANCOVA (with three groups and five covariates) is n = 111. The sample size was therefore 120 participants, comprising 80 schizophrenic patients, 40 deficit and 40 nondeficit patients, and 40 healthy controls. All statistical analyses were performed using IBM SPSS Windows version 22. Tests were two-tailed, and an alpha level of 0.05 indicated a statistically significant effect. Table 1 shows the clinical characteristics of the three study samples. There were no significant differences in age or education level among the three groups. There were more males in both schizophrenic groups as compared with the control group. BMI was significantly lower in patients with deficit schizophrenia than in those without. The work situation was significantly different between the three study samples, the rate of unemployment increasing from controls to nondeficit to deficit schizophrenia subtypes. The SANS, PANS, and BPRS total scores were significantly different between the three study groups and increased from controls to nondeficit to deficit patients groups. Table 2 shows the results of a multivariate GLM analysis with the six TRYCAT levels, the TOTAL-TP index, and QA/ KA ratio as dependent variables and diagnosis (three groups: controls and schizophrenic patients with and without deficit), sex, work status, age, BMI, and education as explanatory variables. We found a significant multivariate effect only for diagnosis. Between-subject effects showed that there were significant univariate effects of diagnosis on IgA responses directed to all TRYCATs (except kynurenic acid and anthranilic acid), TOTAL-TP index, and QA/KA ratio. The same table also shows the estimated mean values of those dependent variables obtained by GLM analysis. Post hoc tests showed that picolinic and xanthurenic acid and TOTAL-TP index were significantly higher in deficit schizophrenia as compared to controls and nondeficit patients. 3-OH-kynurenine was significantly higher in schizophrenic patients than in controls. Quinolinic acid and the QA/KA ratio were significantly higher in schizophrenic patients with deficit as compared to those without.
Results
In order to adjust for possible effects of the drug state of the patients and cigarette smoking, these variables were entered as additional predictors in multivariate GLM analyses with the TRYCATs as dependent variables and the diagnosis (three groups) as an explanatory variable. Seventy-six subjects were taking antipsychotics, 28 antidepressants, 13 mood stabilizers, 30 anxiolytica/hypnotics, while 7 subjects were smoking. There were no significant effects of antipsychotics QA/KA ratio z score quinolinic acid-z score kynurenic acid, BMI body mass index A,B,C denotes the differences among the three categories using protected tests at p = 0.05 In order to delineate the differences in TRYCATs between schizophrenic patients with and without deficit syndrome and controls, an automatic stepwise multinomial logistic regression analysis was carried out with the diagnostic groups as dependent variables, with all six TRYCATs (automatic stepwise method) and age, sex, work status, education, and BMI (forced entry) as explanatory variables (see Table 3 ). We found that five TRYCATs were significantly (χ 2 = 106.09, df = 18, p < 0.001; Nagelkerke = 0.678) associated with these three diagnostic groups, namely picolinic acid (χ 2 = 29.91, df = 2, p < 0.001), quinolinic acid (χ 2 = 11.43, df = 2, p = 0.003), 3-OH-kynurenine (χ 2 = 25.18, df = 2, p < 0.001), kynurenic acid (χ 2 = 9.92, df = 2, p = 0.007), and anthranilic acid (χ 2 = 13.14, df = 2, p = 0.001). Age (χ 2 = 0.15, df = 2, p = 0.927), BMI (χ 2 = 4.61, df = 2, p = 0.100), and education (χ 2 = 3.12, df = 2, p = 0.210) were no significant predictors, while sex (χ 2 = 11.31, df = 2, p = 0.004) had a significant effect. Parameter estimates show that three TRYCATs separated nondeficit schizophrenia from controls, namely picolinic acid and 3-OH-kynurenine (both positively associated) and quinolinic acid (negatively correlated). Four TRYCATs separated deficit schizophrenia from controls, namely picolinic acid and 3-OH-kynurenine (both positively associated) and anthranilic acid and kynurenic acid (both negatively associated). Four TRYCATs separated deficit schizophrenia from nondeficit schizophrenia, namely picolinic acid and quinolinic acid (both positively associated) and anthranilic acid and kynurenic acid (both inversely associated). However, since some of these variables caused multicollinearity (causing some highly significant variables to be eliminated from the final results shown in Table 3 , including xanthurenic acid), we have computed new indexes reflecting the findings in Table 3 , including z score 3HK-Z score QA (zHK-QA), reflecting increased 3HK but relatively lowered QA in nondeficit schizophrenia, and z score XA + z score PA + z score QA-z score AA-z score KA (zXA+PA+ QA-AA-KA), reflecting increased XA, PA, and QA but relatively lowered AA and KA in deficit schizophrenia. These two new indexes together with zQA showed a significant discrimination of the three diagnostic groups (χ 2 = 101.45, df = 14, p < 0.001), with a Nagelkerke comparable to the regression #1 (0.659). zHK-QA (χ 2 = 28.24, df = 2, p < 0.001), zXA+PA+ QA-AA-KA (χ 2 = 39.10, df = 2, p < 0.001), and zQA (χ 2 = 14.49.49, df = 2, p = 0.001) were significant predictors and did not cause significant (multi)collinearity. Table 3 shows that nondeficit schizophrenia was best separated from healthy controls by increased zHK-QA and zXA+PA+QA-AA-KA and deficit schizophrenia from controls by increased zQA, zHK-QA, and zXA+PA+QA-AA-KA. Deficit schizophrenia showed significantly increased QA and zXA+PA+ QA-AA-KA as compared with nondeficit schizophrenia.
In order to examine the associations between the SDS items, on the one hand, and the TRYCATS on the other, multivariate analysis was used with the six SDS items as dependent variables and six TRYCATs together with sex, age, BMI, and education as explanatory variables. Table 4 shows that picolinic acid and anthranilic acid had significant multivariate effects on the six SDS items (after adjusting for the four background variables). Tests for between-subject effects showed that picolinic acid was significantly and positively associated with all six items, whereas anthranilic acid was inversely related with restricted affect, diminished sense of purpose, and a diminished social drive. The new index zXA+PA+ QA-AA-KA was the single best predictor of the six SDS items (multivariate F = 4.79, df = 6/105, p < 0.001). Tests of betweensubject effects showed univariate effects on restricted affect (F = 8. In order to examine the associations between the SANS, PANSS, and BPRS, on the one hand, and the six TRYCATS on the other, multivariate analysis was used with the rating scales as dependent variables and six TRYCATs together with sex, work, age, BMI, and education as explanatory variables. Table 5 shows that picolinic acid and anthranilic acid had significant multivariate effects on the three rating scales (after adjusting for the sociodemographic data). Between-subject analyses showed that picolinic acid was significantly and positively associated with the three rating scales, whereas anthranilic acid was inversely associated with the rating scale scores. The new index zXA+PA+QA-AA-KA was the single best predictor of the SANS, PANSS, and BPRS scales (multivariate F = 9.05, df = 3/107, p < 0.001). Tests of betweensubject effects showed univariate effects on SANS (F = 27.38, df = 1/109, p = 0.001), PANSS (F = 17.23, df = 1/109, p < 0.001), and BPRS (F = 13.32, df = 1/109, p < 0.001).
In order to delineate the predictors of the PANS (positive, negative, general) and SANS (flattening, analogia, avolition, anhedonia, attention) subscales, automatic stepwise regression analyses were employed with the subscales as dependent v a r i a b l e s a n d a l l T RY C ATs t o g e t h e r w i t h t h e sociodemographic data as explanatory variables. Table 6 shows that the PANS positive subscale was not related to any of the TRYCATs. The PANS negative subscale was positively associated with picolinic acid and negatively with anthranilic acid. PANS general subscale was positively associated with 3-OH-kynurenine. SANS flattening was predicted by increased picolinic acid and quinolinic acid as well as decreased anthranilic acid levels; SANS alogia by picolinic acid; SANS avolition by picolinic acid (positive), 3-OHkynurenine (positive), and anthranilic acid (negative association); SANS anhedonia by picolinic acid (positive) and anthranilic acid (negative); and SANS attention with 3-OHkynurenine (positive).
The new index zXA+PA+QA-AA-KA was the single best predictor of the PANS positive, PANS negative, and PANS general subscales (multivariate F = 7.46, df = 3/107, p < 0.001). Tests of between-subject effects showed no significant effects on the PANS positive score (F = 3.88, df = 1/109, p = 0.051), while there were highly significant effects on PANSS negative (F = 22.04, df = 1/109, p < 0.001) and PANSS general (F = 16.02, df = 1/109, p < 0.001) subscale scores. The index zXA+PA+QA-AA-KA was also the single best predictor of the five SANS subscale scores (multivariate NON nondeficit schizophrenia, DEFICIT deficit schizophrenia, z3HK-QA: z score 3-OH-kynurenine (3HK)-Z score quinolinic acid (QA), zXA+PA+QA-AA-KA z score xanthurenic acid (XA) + z score picolinic acid (PA) + z score QA-z score anthranilic acid (AA)-z score kynurenic acid (KA), zQA z score QA 
Discussion
The first major finding of this study shows there to be significant differences in IgA responses directed against TRYCATs between deficit and nondeficit schizophrenia, with both patient groups being significantly discriminated from healthy controls. These findings suggest that different patterns of TRYCAT activation may contribute to the distinct features, and more severe outcomes of deficit schizophrenia. The results also show that deficit, but not nondeficit, schizophrenia is accompanied by TRYCAT pathway activation (as estimated by the sum of z scores of the 6 IgA responses directed against TRYCATs), although nondeficit schizophrenia is accompanied by specific changes in IgA responses directed to TRYCATs (see next paragraph). Prior research has reported that the TRYCAT pathway is induced in schizophrenia, with kynurenate levels being increased and tryptophan levels being decreased, indicating raised levels of tryptophan degradation [21] [22] [23] [24] [25] [26] . However, as previous investigations did not separate deficit from nondeficit schizophrenia, it is unknown as to whether different subtypes of schizophrenia explained the TRYCAT pathway induction. Another important methodological difference is that the study reported here assayed IgA responses directed to TRYCATs, whereas previous studies measured TRYCAT concentrations in the blood, CSF, and brain. Previously, we have shown that in normal and pregnant women, IgA responses directed to TRYCATs are associated with increased bacterial translocation of commensal gramnegative bacteria, suggesting that the IgA responses to TRYCATs are, in part, induced by increased bacterial translocation due to increased gut permeability [49] . Previously, a significant association between gut dysfunction and an activated TRYCAT pathway was established [31] , with an increase in gut permeability and alterations in the microbiome being proposed to play a role in schizophrenia [13] . As such, increased gut permeability, by driving an increased immune activation and oxidative stress, may activate IDO [40, 41] , leading to increased TRYCATs production and, consequently, increased IgA-mediated responses to those TRYCATs [48] . These responses therefore may reflect mucosa-associated changes in TRYCATs production as well as immune responses mounted against these changes. As such, measuring IgA responses directed against TRYCATs is probably a more sensitive method than assaying TRYCAT concentrations as the former measures how the immune system perceives and reacts to changes in the TRYCAT pathway. Such TRYCAT induction is also likely to have consequences for brain functions as plasma levels of quinolinic acid, kynurenine, and 3-OH-kunyrenine determine brain concentrations of quinolinic acid [50] . Such changes are likely to be part of a gut-brain axis [51] . Future research in schizophrenia should compare different assays of TRYCAT pathway activation (namely assays of IgA responses directed against TRYCATs with TRYCAT plasma concentrations measured using classical methods, including high performance liquid chromatography) in relation to increased gut permeability and possible sources of mucosa-derived TRYCAT activation. The current study indicates that nondeficit schizophrenia versus the healthy control state is characterized by increased IgA-mediated responses directed to 3-OH-kynurenine and relatively increased picolinic acid but lowered quinolinic acid levels. The current findings do not replicate the results of previous studies showing increased levels of kynurenic acid and anthranilic acid coupled to lowered levels of xanthurenic acid in schizophrenia [27, 28] . In contrast, the current study shows that kynurenic acid and anthranilic acid were relatively lowered in the combined schizophrenia groups versus controls with respect to increased levels of noxious TRYCATs. Thus, the current results do not corroborate the hypothesis that increased kynurenic acid plays a key role in the pathophysiology of schizophrenia [29, 30] . Increased levels of 3-OH-kynurenine, together with lowered levels of kynurenic acid, may be the consequence of increased kynurenine 3-monooxygenase (KMO) function. These findings contrast to prior data suggesting lowered KMO function in schizophrenia [52] . However, as discussed above, it is difficult to contrast our current results with those carried out previously, as deficit and nondeficit schizophrenia groups were not differentiated in previous studies.
Our findings suggest that nondeficit schizophrenia may be accompanied by an increased inflammatory and oxidative potential, with consequent changes in the TRYCAT pathways likely to contribute to other data and models of the pathophysiological underpinnings of schizophrenia, including alterations in dopaminergic and NMDAr activity. Indeed, 3-OHkynurenine is a TRYCAT with neurotoxic and excitotoxic properties, although the neurotoxic effects are exerted at supra-physiological concentrations [53] . This TRYCAT produces reactive oxygen species, which can contribute to cell death [53] and is also a driver of many other pathophysiological processes. Interestingly, IgA responses to quinolinic acid were decreased in nondeficit schizophrenia compared to deficit schizophrenia. Given that the excitotoxic effects of quinolinic acid are mediated by increased ionic flow via the NMDAr, this suggests links to classical models of schizophrenia that have posited an important role for the NMDAr. The findings of the current study suggest that lowered NMDAr activity may be more closely related to decreased quinolinic acid rather than to increased kynurenic acid levels. Moreover, the results suggest that relatively lowered quinolinic acid levels may protect against deficit schizophrenia. Although picolinic acid is excitatory, it may antagonize the neurotoxic activities of quinolinic acid [54] . Perhaps more important, picolinic acid activates macrophages and induces the production of macrophage inflammatory protein 1-alpha (MIP-1α) (or CCL3) and MIP-1β [16] . Previously, we have shown that schizophrenia is accompanied by a highly specific increase in MIP-1α together with other pro-inflammatory factors [7] . Increased levels of MIP-1α, in turn, induce the production and release of other pro-inflammatory cytokines, which are increased in schizophrenia, including interleukin-6 [10] . Moreover, picolinic acid enhances nitric oxide production, macrophage-mediated cytotoxicity, and phagocyte effector functions, as well as the microbicidal activity of macrophages [16] . Picolinic acid is an inhibitor of dopamine betamonooxygenase, the enzyme that catalyzes the oxidation of dopamine into noradrenaline [55] , suggesting that increased picolinic acid may increase dopamine levels. A major finding of our study is that patients with primary deficit schizophrenia show much higher IgA responses to picolinic, xanthurenic, and quinolinic acids, an increased quinolinic acid/kynurenic acid ratio, and relatively lowered anthranilic acid and kynurenic acid levels as compared to nondeficit schizophrenia and additionally increased IgA responses to 3-OH-kynurenine, picolinic acid, and xanthurenic acid as compared to controls. Likewise, the negative symptoms of schizophrenia (as measured with the SDS, SANS, and PANSS), but not the positive symptoms, are strongly associated with increased IgA responses to picolinic acid and lowered levels of anthranilic acid. These findings are important to the pathophysiology of deficit schizophrenia as discussed below.
Kynurenic acid has negative immune regulatory properties, while anthranilic acid and its derivatives have antiinflammatory and antimicrobial activities, while both TRYCATs display antioxidant properties [56] [57] [58] . Therefore, decreased levels of these TRYCATs in deficit schizophrenia may further elevate the inflammatory and oxidative potential and in addition lower resistance to infectious agents, including bacterial translocation. These effects may further augment the pro-inflammatory and oxidative effects of increased picolinic acid and 3-OH-kynurenine. Moreover, inhibition of kynurenic acid synthesis increases dopamine turnover, while kynurenic acid reduces dopamine levels [59, 60] . Lowered levels of kynurenic acid may also indicate lowered activity of KAT2, the major determinant of brain kynurenic acid, in schizophrenia. mKat-2 −/− mice show lowered total KAT activity and kynurenic acid levels and manifest abnormal motor coordination and hyperactivity and neuroanatomical changes, including enlarged dendritic spines [61] . The detrimental effects of increased quinolinic acid and xanthurenic acid may contribute to the onset, severity, and maintenance of negative symptoms and thus deficit schizophrenia. Quinolinic acid has neurotoxic and excitotoxic properties, activates the NMDArs, causes neuronal dysfunction, has pro-inflammatory and oxidative effects leading to lipid peroxidation, potentiates reactive oxygen species, increases glutamate release thereby causing glutamate accumulation, depletes energy stores, and impairs mitochondrial functions [15, 53, 56, 62] . In addition, increased 3-OH-kynurenic acid potentiates the excitotoxic effects of quinolinic acid in rodent models [63] .
Xanthurenic acid has some neuroprotective functions by lowering 3-OH-kynurenine levels [19] . This TRYCAT also inhibits vesicular glutamate transport (VGLUT), thereby reducing AMPA and NMDA receptor-mediated synaptic transmission and glutamate receptor-mediated excitatory postsynaptic potentials [20, 64] . Moreover, xanthurenic acid has putative agonistic activity at metabotropic glutamate (mGLU2/ 3) receptors, thereby causing presynaptic inhibition and reducing both inhibitory and excitatory activities of postsynaptic potentials and negatively regulating the activity of 5-HT 2A receptors restraining excitatory inputs to cortical neurons [28, 65] . In this respect, it is interesting to note that the neuroprotective effects of picolinic acid against excitotoxins require intact glutamate inputs [66] . Nevertheless, xanthurenic acid has many detrimental effects, including apoptosis, impairment of mitochondrial functions, and most importantly hyperactivation of cationic channels, thereby increasing intracellular calcium concentration and excitatory functions in brain neural circuits [20] . Such effects may dramatically increase neuronal damage and cause disorders in glutamate transmission, restraining presynaptic transmission while activating NMDArs. Likewise, the increase of the negative symptoms from controls to nondeficit and deficit schizophrenia may be related to increasing levels of picolinic acid causing more immune activation and inflammation, and lowering levels of kynurenic and anthranilic acid causing attenuated neuroprotective and neuroinhibitory potential while increasing dopamine turnover. Our results do not allow conclusions to be drawn as to whether changes in IgA isotype responses to TRYCATs or noxious TRYCATs are a trait (genetic or prodromal) marker of deficit schizophrenia. If so, such changes could play a role in the twohit hypothesis of schizophrenia, namely alterations in TRYCAT patterning may cause neurodevelopmental processes which lead to schizophrenia in later life [1] [2] [3] [66] [67] [68] through the many neuroprogressive effects of TRYCATs [69] . Nevertheless, it is our new hypothesis that a highly specific deficit in natural IgM-mediated regulatory responses directed against noxious TRYCATs underpins deficit schizophrenia [70] and that this defect in the compensatory (anti)inflammatory reflex system [70, 71] together with mucosa-derived activation of the TRYCAT pathway (as measured with IgA responses to TRYCATs) contributes to neuroprogression, negative symptoms, and deficit schizophrenia [70] . These findings support the theory that neuroprogressive pathways are involved in deficit schizophrenia and that targeting these pathways could be a valid treatment option [72] . The highly specific alterations in IgA responses underpinning deficit and nondeficit schizophrenia are therefore new drug targets in both disorders. For example, an adequate treatment for deficit schizophrenia would consist of anthranilic acid esters, which are strong anti-inflammatory molecules, KAT II activators, and KMO inhibitors.
Some limitations of this study warrant discussion. First, its cross-sectional design does not allow the establishment of firm causal inferences. Second, although plasma levels of noxious TRYCATs, including quinolinic acid, determine in part brain levels of those TRYCATs, the data presented here do not necessarily represent indicants of significant differences in brain functioning between deficit and nondeficit schizophrenia. The main strengths of our study rest on the recruitment of a well characterized sample, and on the employment of welldelineated laboratory assays. Another strength is that we employed multivariate statistical analyses in order to control for different sources of nuisance, including age and sex, and that results of univariate tests were interpreted only when the multivariate effects were significant, thereby reducing type I errors. Although previous studies in depression established significant sex-related differences in the TRYCAT pathway and IDO activation [73] , this study was unable to detect such effects. While previous studies detected that IDO activity in peripheral blood mononuclear cells may increase in old age (especially in nanogenarians) [74] , we included patients with a mean age around 40 years (± SD of 11) and could not find any significant age effects.
In conclusion, the results show that both nondeficit and deficit schizophrenia are accompanied by mucosa-associated alterations in the TRYCAT pathway. Our results further support the theory that deficit schizophrenia is a distinct subtype of schizophrenia and is discriminated from nondeficit schizophrenia by specific alterations in the TRYCAT pathway. Figure 1 provides an overview of the findings and the possible role of the different TRYCATs in nondeficit and deficit schizophrenia. Thus, both schizophrenia subtypes are accompanied by increased 3-OH-kynurenine levels while picolinic acid increases from nondeficit to deficit schizophrenia. These TRYCAT pathway changes may be associated with increased inflammatory and oxidative potential and contribute to alterations in dopaminergic activity. While nondeficit schizophrenia is characterized by lowered quinolinic acid levels, deficit schizophrenia is accompanied by increased quinolinic acid and xanthurenic acid, which, together with increased 3-OHkynurenine and picolinic acid, may further increase inflammatory, oxidative stress and neurotoxic and excitotoxic processes.
